People In Brief
This article was originally published in The Gray Sheet
Executive Summary
LaViolette ventures from Boston Sci: Former Boston Scientific Chief Operating Officer Paul LaViolette will join venture capital firm SV Life Sciences next month as a venture partner in the company's Boston office and medical technology segment. LaViolette relinquished the COO position July 1 as part of an executive restructuring at Boston Scientific (1"The Gray Sheet" June 9, 2008, p. 8). LaViolette will leave the device firm outright at the end of the year after six months as a company advisor and about 15 years as a top executive. SVLS's device portfolio includes laser ablation firm CardioFocus, ventricular assist device company MicroMed, and diabetes product firm Insulet. The venture firm points out that LaViolette integrated more than 20 acquisitions during his time at Boston Scientific
You may also be interested in...
People In Brief
Medtronic's DeMane goes VC: Former Medtronic Chief Operating Officer Michael DeMane joins health care venture capital firm Thomas, McNerney & Partners April 3. Thomas, McNerney's device portfolio includes atrial fibrillation firm Atritech and continuous glucose monitor developer ArKal Medical. DeMane, who had served in various executive roles with Medtronic since 2000, left the device giant last year when the firm elected to remove the COO position (1"The Gray Sheet" May 5, 2008, p. 4). He is the second big device company COO to move to the venture capital sector in the past three months, with Paul LaViolette leaving Boston Scientific for SV Life Sciences in January (2"The Gray Sheet" Dec. 22, 2008, p. 21)
People In Brief
Medtronic's DeMane goes VC: Former Medtronic Chief Operating Officer Michael DeMane joins health care venture capital firm Thomas, McNerney & Partners April 3. Thomas, McNerney's device portfolio includes atrial fibrillation firm Atritech and continuous glucose monitor developer ArKal Medical. DeMane, who had served in various executive roles with Medtronic since 2000, left the device giant last year when the firm elected to remove the COO position (1"The Gray Sheet" May 5, 2008, p. 4). He is the second big device company COO to move to the venture capital sector in the past three months, with Paul LaViolette leaving Boston Scientific for SV Life Sciences in January (2"The Gray Sheet" Dec. 22, 2008, p. 21)
LaViolette Sees Opportunities Behind The Risks In Down Economy
Paul LaViolette has a unique perspective on the device industry, having worked with some of the biggest and most established firms as well as brand new start-ups